1. Introduction {#sec1}
===============

Alzheimer\'s disease (AD), a leading cause of morbidity and mortality in the elderly, is characterized by progressive cognitive decline and neuropathological features including amyloid plaques and neurofibrillary tangles. There is currently no cure for AD. Current US Food and Drug Administration-approved drugs for the treatment of AD include cholinesterase inhibitors such as donepezil, rivastigmine and galantamine, and memantine, an N-methyl-D-aspartate blocker. These drugs have modest symptomatic effects but do not have profound disease-modifying effects [@bib1]. Attempts to treat amyloid toxicity are underway by a number of groups [@bib2], [@bib3], as are a variety of other approaches [@bib4]. A complete review of current AD therapies can be found in a 2018 publication in this journal [@bib5].

Resveratrol, a polyphenol, has received considerable attention based on molecular, animal, and clinical work [@bib6]. Antiinflammatory effects of resveratrol are suggested by evidence of inhibition of TNF-α and nitric oxide (NO) in mouse microglial cell lines [@bib7]. Resveratrol has been proposed to have antioxidant activity both through free radical scavenging [@bib8] and through upregulation of antioxidant enzymes [@bib6]. Finally, neuroprotection has been proposed based on reducing cell death via activation of sirtuins (including SIRT1), resulting in protection against peptide aggregate [@bib9]. In a 6-month study on the use of resveratrol (200 mg daily) in 46 healthy overweight people aged 50-80 years, the resveratrol group showed better Auditory Verbal Learning Test scores [@bib10] and showed significant increases in functional connectivity of the hippocampus to frontal, parietal, and occipital areas of the brain than the placebo group [@bib11]. Despite this evidence, there have been no conclusive results on the efficacy of resveratrol in human trials [@bib6], [@bib12], [@bib13]. A recent meta-analysis on the efficacy of resveratrol supplementation on cognitive performance found mixed results in currently published clinical research, with a plurality of studies reporting no significant effect on cognitive performance in the general population except a small effect in improving delayed recognition [@bib13]. There are a few ongoing trials investigating the efficacy of resveratrol in mild cognitive impairment and moderate AD, with different routes of administration, although results from these trials are only beginning to be published [@bib8], [@bib14], [@bib15], [@bib16].

Resveratrol has been shown to be well tolerated and pharmacologically safe at doses up to 5 g/day [@bib17]. A recent clinical trial using high-dose resveratrol (2000 mg/day) in patients with mild to moderated AD found that the agent and its metabolites were present in cerebrospinal fluid, suggesting central availability [@bib18], [@bib19]. Compared with the placebo group, the resveratrol group showed markedly reduced cerebrospinal fluid MMP9 levels at week 52 [@bib19]. Cerebrospinal fluid Aβ~40~ and plasma Aβ~40~ levels declined more in the placebo group than the resveratrol-treated group at week 52; however, brain volume loss was greater in the resveratrol than placebo group [@bib18], [@bib19]. It is difficult to reconcile these effects as potentially beneficial, although a hypothesis has been suggested that resveratrol has potent antiinflammatory effects in the AD brain---with decreased CNS edema as the etiology of greater brain volume loss. The study also reported less decline in activities of daily living (ADLs) in the treated group, although the study was inadequately powered to determine clinical outcomes.

In an initial, double-blind, placebo-controlled, prospective clinical trial, positive effects in AD with a "metabolic enhancer" that contains low-dose resveratrol (5 mg/day), glucose, and malate (RGM) have been reported [@bib20], [@bib21], [@bib22]. Glucose is the physiological precursor of substrates of oxidative metabolism in the brain, and malate is an intermediate of the energy-providing Krebs cycle. Glucose and malate can provide reducing equivalents (electrons) to regenerate the reduced form of resveratrol and do so under normal regulation of brain cell metabolism. All three ingredients are classified by the US Food and Drug Administration as generally recognized as safe. The "metabolic enhancer" also contains pharmaceutical flavorings, to mask the very sour taste of malate. The preparation is given with unsweetened grape juice because the natural sugar in grape juice is glucose. A preparation has therefore been developed, which has been designed to help the body regulate free radical metabolism rather than simply to quench free radicals. The study tested the addition of RGM to patients who were already receiving anticholinergic treatment by taking stable doses of donepezil. The results of this trial were promising. The addition of RGM to anticholinergic treatment seems to have beneficial effects on cognition without causing any significant side effects.

Based on these results, we hypothesized that this preparation may be useful as part of an evolving "AD treatment regimen" worthy of replication by more rigorous methods. Specifically, we aimed to test the hypothesis that the combination of RGM would significantly reduce clinical progression of AD and have beneficial effects over placebo on measures of ADL limitations, psychiatric and behavioral symptoms in a pilot double-blind placebo-controlled trial. The specific goals of this study were (1) to use a multisite, single-center model to test the safety and efficacy of RGM in well-characterized patients with AD by conducting the trial with exact replication of subjects, agent, outcomes, and design (i.e., 6 months of exposure) of the original study and (2) to extend the double-blind observation period to assess efficacy at 12 months.

2. Methods {#sec2}
==========

2.1. Study design {#sec2.1}
-----------------

This is a pilot study with placebo-controlled, parallel design. After enrollment, subjects were randomly assigned to the treatment or placebo group and followed up at 3, 6, and 12 months. Enrollment began in January 2007 and ended in September 2009. From power analysis performed based on preliminary data available at the time, 35 participants per group were expected to be needed to achieve 80% power to detect a difference in mean Alzheimer\'s Disease Assessment Scale--cognitive subscale (ADAS-cog) change between the active and placebo group, with α = 0.05. Enrollment target was set to be 100 (50 per group) to allow for attrition. Actual enrollment was 39, of which 32 were randomized. Cognitive, behavioral, and clinical assessments were administered at baseline and each follow-up visit. Subjects were treated with RGM or placebo for a total of 12 months. The primary outcome measure was change in ADAS-cog [@bib23]. Secondary outcome measures were ADCS Clinician\'s Global Impression of Change (ADCS-CGIC) [@bib24], Mini--Mental State Examination (MMSE) [@bib25], Alzheimer\'s Disease Cooperative Study--Activities of Daily Living Scale (ADCS-ADL) [@bib26], and Neuropsychiatric Inventory (NPI) [@bib27]. Study outcomes were assessed by trained clinicians who were blind to participant\'s treatment assignment. Randomization was centrally generated to determine group assignment with equal probability of assignment to drug and placebo, stratified by site. Safety measures included clinical and laboratory indicators. The study was approved by the local institutional review boards and registered at [ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0020} ([NCT00678431](NCT00678431){#intref0025}).

2.2. Participants {#sec2.2}
-----------------

Patients were recruited from the Mount Sinai Alzheimer\'s Disease Research Center. Primary inclusion criteria were (1) a probable or possible AD diagnosis according to the National Institute of Neurological and Communicative Disorders and Stroke--Alzheimer\'s Disease and Related Disorders Association (NINCDS/ADRDA) criteria [@bib28]; (2) age 50 or older; (3) MMSE score 12-26 [@bib25]; (4) living in the community; (5) stable medical condition and stable use of nonexcluded medications; (6) supervision available for administration of study medications; (7) availability of a study partner to accompany subject to all scheduled visits and complete informant-based assessments; (8) Modified Hachinski score \< 4 [@bib29]; (9) able to complete baseline assessments in English or Spanish; and (10) able to ingest an oral agent. Exclusion criteria included (1) active liver or renal disease; (2) active life-threatening neoplastic disease; (3) use of another investigational agent within 2 months of the screening visit; (4) history of clinically significant stroke; (5) current evidence or history in the past 2 years of seizures, head injury with loss of consciousness, and/or immediate confusion after the injury; (5) current DSM-IV diagnosis for major psychiatric disorder; and (6) blindness, deafness, language difficulties, or other disability that may interfere with assessment. Excluded medications included those with significant central anticholinergic or antihistaminic effects and experimental drugs. Psychiatric medications had to be stable. A validated Spanish version was administered by competent speakers. Written informed consent was provided by all subjects before enrollment.

2.3. Intervention {#sec2.3}
-----------------

Study medication (RGM) was prepared to adhere to regimen used in the study by Blass and Gordon (2004) [@bib20]. The active daily treatment regimen consisted of 5 g dextrose, 5 g malate, and 5 mg resveratrol per dose. It was administered twice a day in liquid form and taken in a 15 mL volume dissolved in unsweetened commercial red grape juice. Placebo contained sucrose and lemon juice and was indistinguishable by color or taste from the active preparation.

2.4. Outcomes {#sec2.4}
-------------

The primary outcome for this study was rate of change in the cognitive portion of the ADAS-cog (range = 0-70), a psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis [@bib23]. Higher scores indicate more impairment. A positive change score indicates cognitive worsening. Secondary outcomes include change scores on the MMSE (range = 0-30, higher scores indicating better cognition, a positive change score indicates cognitive improvement), ADCS-ADL (range = 0-78, higher scores indicating better function, a positive change score indicates functional improvement) [@bib26], NPI (higher scores indicating worse behavior, a positive change score indicates worsening behavior) [@bib27], and ADCS-CGIC [@bib24].

2.5. Safety assessments {#sec2.5}
-----------------------

Participants received physical and neurologic examinations and vital signs at each visit. Safety measures included standard reporting of any adverse events (AEs) or endorsement of items from a "symptom checklist" that directly inquired about known side effects of the agents. These were collected at each visit as well as at any time that the informant contacted study staff. If a participant withdrew, an early termination visit similar to a baseline visit was scheduled. An independent Data and Safety Monitoring Board reviewed data quarterly.

2.6. Statistical analysis {#sec2.6}
-------------------------

Baseline characteristics of the study groups were compared using Fisher\'s exact test for categorical variables and Wilcoxon signed-rank test for continuous variables. Change scores from baseline in ADAS-cog, MMSE, and ADCS-ADL between treatment and placebo groups were compared at each follow-up visit. Group differences in the rate of change in the outcome measures were examined using generalized estimating equations [@bib30]. Differences in the proportion of subjects reporting worsening on the ADCS-CGIC were examined using logistics regressions. Models included age, gender, education, and baseline scores as covariates. Safety analyses were based on summary listings of AEs. Differences in the rate of adverse events were compared using Fisher\'s exact test. Investigators classified AEs by severity and causality. Analyses were based on an intention-to-treat population, including all randomly assigned participants with at least one postbaseline observation. All tests were two-sided. *P*-value of 0.05 was considered statistically significant and set a priori. Blinding of investigators was maintained until after outcomes were determined. All analyses were conducted using Stata 13 [@bib31].

3. Results {#sec3}
==========

3.1. Baseline characteristics {#sec3.1}
-----------------------------

Thirty-nine subjects were screened (6 screen fail, 1 early termination). Thirty-two subjects were randomized (17 treatment and 15 control), of whom 3 subjects (1 treatment and 2 control) withdrew consent ([Fig. 1](#fig1){ref-type="fig"} CONSORT flow diagram) [@bib32]. The study included 29 subjects (16 treatment and 13 control) from whom data are available. Subjects were successfully randomized into treatment and placebo groups with similar characteristics on age (mean = 80 ± 7.7), gender (56.6% male), and education (mean = 15 ± 4.6) ([Table 1](#tbl1){ref-type="table"}). There were no differences between treatment and control groups on any of the screening variables.Fig. 1Consort Diagram and Disposition by Treatment Group.Table 1Baseline characteristics by the treatment groupVariablesControl group (n = 13)Treatment group (n = 16)*P*-valueAge, mean ± standard deviation79.3 ± 6.580.5 ± 8.60.6850Male, n (%)8 (61.5)9 (56.3)0.7737Education, mean ± standard deviation14.1 ± 5.215.7 ± 4.10.3596ADAS-cog, mean ± standard deviation29.2 ± 8.926.4 ± 11.90.4901ADCS-ADL, mean ± standard deviation46.6 ± 7.649.1 ± 10.30.4805MMSE, mean ± standard deviation19.4 ± 3.818.1 ± 4.90.7239NPI, mean ± standard deviation7.9 ± 11.85.4 ± 5.90.4975[^1]

3.2. Change scores from baseline by the treatment group {#sec3.2}
-------------------------------------------------------

[Table 2](#tbl2){ref-type="table"} reports scores for the outcomes by treatment and control groups at each visit. Changes in outcomes are shown graphically in [Fig. 2](#fig2){ref-type="fig"}. For ADAS-cog, mean change scores from baseline were −0.83 ± 7.88, 1.45 ± 6.27, and 5.33 ± 14.46 at month 3, 6, and 12 for the control group, and −0.21 ± 6.57, 1.33 ± 6.10, and 2.00 ± 15.36 for the treatment group. For MMSE, mean change scores from baseline were 0.09 ± 2.39, −1.27 ± 2.65, and −3.27 ± 3.47 at month 3, 6, and 12 for the control group, and 1.15 ± 2.91, 0.45 ± 1.97, and −1.73 ± 4.43 for the treatment group. For ADCS-ADL, mean change scores from baseline were −1.83 ± 7.43, −1.27 ± 8.81, and −5.58 ± 11.37 at month 3, 6, and 12 for the control group, and −0.64 ± 5.47, −1.83 ± 8.31, and −0.75 ± 9.00 for the treatment group. For NPI, mean change scores from baseline were 4.67 ± 6.95, 2.27 ± 12.46, and 3.17 ± 10.92 at month 3, 6, and 12 for the control group, and −1.64 ± 3.73, −0.25 ± 4.94, and 0.75 ± 6.69 for the treatment group. Differences were statistically insignificant.Table 2Outcomes at each visit by the treatment groupVariablesControl group (n = 13)Treatment group (n = 16)ADAS-COGVisitMeanStandard deviationMeanStandard deviation029.238.9026.4411.93327.0010.6125.9312.82627.9110.1226.8315.141233.1718.6229.9214.13ADCS-ADL046.627.5749.0610.26344.2510.0850.2111.27645.0912.7448.8310.281240.5013.2749.3310.51MMSE019.423.7818.074.86319.583.9019.215.65618.274.9819.834.841215.426.5416.927.67NPI07.9211.785.445.90311.6717.563.366.8968.739.425.088.351210.1711.036.257.51[^2]Fig. 2Mean change scores from baseline at each follow-up visit in treatment and placebo groups. Vertical bars represent standard deviation. Blue arrow indicates direction of improvement. (A) Positive change scores in ADAS-cog indicate worsening impairment from baseline. (B) Positive change scores in ADCS-ADL indicate improvement from baseline. (C) Positive change scores in MMSE indicate improvement from baseline. (D) Positive change scores in NPI indicate worsening impairment from baseline. Abbreviations: ADAS-cog, Alzheimer\'s Disease Assessment Scale--cognitive subscale; MMSE, Mini--Mental State Examination; ADCS-ADL, Alzheimer\'s Disease Cooperative Study--Activities of Daily Living Scale; NPI, Neuropsychiatric Inventory.

[Table 3](#tbl3){ref-type="table"} shows generalized estimating equation estimates of rate of change over time by the treatment group. At baseline, NPI was significantly lower in the treatment than control group (*P* = .025). Over time, ADAS-cog increased (*P* = .05) and MMSE decreased (*P* = .003) for the control group. There were no statistically significant differences in rate of change over time by the treatment group in the outcomes.Table 3GEE estimates of rate of change in outcomesVariablesADAS-COG*P*-valueADCS-ADL*P*-valueMMSE*P*-valueNPI*P*-valueEstimate (SE) \[95% CI\]Estimate (SE) \[95% CI\]Estimate (SE) \[95% CI\]Estimate (SE) \[95% CI\]Treatment group2.087 (3.745) \[−5.253, 9.426\]0.577−0.060 (3.587) \[−7.091, 6.971\]0.9871.336 (1.281) \[−1.175, 3.848\]0.297−6.944 (3.102) \[−13.020, -0.863\]0.025Visit0.680 (0.349) \[−0.003, 1.363\]0.051−0.387 (0.354) \[−1.081, 0.307\]0.274−0.367 (0.122) \[−0.606, −0.128\]0.003−0.089 (0.447) \[−0.965, 0.787\]0.842Treatment group × visit−0.451 (0.612) \[−1.649, 0.748\]0.4620.419 (0.491) \[−0.543, 1.382\]0.3930.036 (0.191) \[−0.337, 0.410\]0.8500.368 (0.485) \[−0.584, 1.319\]0.449[^3]

At the 3-month visit, substantially fewer subjects in the treatment group worsened marginally compared with the control group as measured by CGIC (15.4% vs. 50.0%, *P* = .07) (data not shown). At the 12-month visit, there were no statistically significant differences in rate of change over time by the treatment group in CGIC.

3.3. Adverse events {#sec3.3}
-------------------

During the study, 7 subjects reported a total of 36 adverse events (29 AEs from 4 control subjects and 7 AEs from 3 treatment subjects) ([Table 4](#tbl4){ref-type="table"}). None of these were deemed to be study related. The most common AE was falls (in 3 control subjects). Agitation also occurred more than once (both in control subjects). Among subjects who reported AEs, fewer adverse events per subject were reported in the treatment group (2.3 vs. 7.3 events per subject, *P* = .059).Table 4Number of adverse events by systemSystemControl group (n = 13)Treatment group (n = 16)Psychiatric disorders[∗](#tbl4fnlowast){ref-type="table-fn"}68Nervous system disorders[†](#tbl4fndagger){ref-type="table-fn"}44Gastrointestinal disorders[‡](#tbl4fnddagger){ref-type="table-fn"}62Cardiac disorders[§](#tbl4fnSection){ref-type="table-fn"}32Injury, poisoning, or procedural complications[¶](#tbl4fnpara){ref-type="table-fn"}52Musculoskeletal and connective tissue disorders[‖](#tbl4fnVerbar){ref-type="table-fn"}11Skin and subcutaneous tissue disorders[\#](#tbl4fnhash){ref-type="table-fn"}11Renal and urinary disorders[∗∗](#tbl4fnlowastlowast){ref-type="table-fn"}01Vascular disorders[††](#tbl4fndaggerdagger){ref-type="table-fn"}10Eye disorders[‡‡](#tbl4fnddaggerddagger){ref-type="table-fn"}20[^4][^5][^6][^7][^8][^9][^10][^11][^12][^13]

4. Discussion {#sec4}
=============

This study tested the efficacy and safety of low-dose resveratrol in a cohort of well-characterized patients with AD. Despite inadequate recruitment, positive trends were noted in four clinical outcome measures. At 12 months, change scores on ADAS-cog, MMSE, ADCS-ADL, or NPI all showed less deterioration in the treatment than the control group; however, none of the change scores reached statistical significance. Results showed that low-dose oral resveratrol is safe and well tolerated. The most common AE were falls, all in the control group. None of which were deemed to be study related.

Human studies on low-dose resveratrol are scarce. We found only one trial that examined the effect of high-dose resveratrol in individuals with mild to moderate AD using data from the ADCS [@bib18], [@bib19]. Compared with the ADCS sample, our sample has similar levels of education (15.7 ± 4.1 years vs. 15.5 ± 3.0 years) but is older (average age 80.5 ± 8.6 vs. 69.8 ± 7.7) and has fewer females (56.3% vs. 63%). At baseline, subjects in the treatment group in our sample also have lower MMSE (18.1 ± 4.9 vs. 20.2 ± 4.4), lower ADCS-ADL (49.1 ± 10.3 vs. 63.7 ± 10.8), higher ADAS-cog (26.4 ± 11.9 vs. 25.3 ± 10.1), and lower NPI (5.4 ± 5.9 vs. 7.5 ± 7.9). Similar to our study, data from the ADCS study reported no significant effects of high-dose resveratrol on ADAS-cog, MMSE, or NPI at 52 weeks, although no actual values at week 52 were reported. Although both studies found less decline in the treatment group in ADCS-ADL, the differences were statistically significant in the ADCS study but not in the present study [@bib18], [@bib19]. Together, these data suggest that our sample is constituted of a typical group of AD patients with cognition and function in the mild-moderate range.

Mechanisms involved in high- and low-dose resveratrol interventions may differ. High-dose studies, such as by Turner et al., consider SIRT1 activation as a potential mechanism and point to low bioavailability but high bioactivity [@bib33], [@bib34], to select a maximally safe and well-tolerated dose for their study. Our model focused on metabolic enhancement via reduction of free radicals, which led to the use of low-dose resveratrol similar to that obtained in foods [@bib35]. Glucose and malate, Krebs cycle intermediates were added to increase the rate of mitochondrial metabolism. Despite these proposed mechanistic differences, both safety and efficacy results with high- and low-dose resveratrol were not dissimilar.

This study has several limitations. The study was discontinued before recruitment goals were achieved due to difficulties in recruitment and in keeping the study product stable. The study was underpowered to detect differences in clinical outcomes between treatment and control groups. Data in this study suggest that to achieve 80% power in detecting group differences at .05 level, 48 subjects in each group are needed for ADCS-ADL, 56 subjects in each group for NPI, and 425 subjects in each group for ADAS-cog. Because the low-dose resveratrol is not unlike that obtained in foods [@bib35], interactions with metabolic, environmental, and other nutrition intake may overwhelm the possible beneficial effects. Designing studies to take such complexity into account is challenging.

5. Conclusion {#sec5}
=============

This study showed that low-dose oral resveratrol is safe and well tolerated. However, partly because the study was underpowered to detect differences in clinical outcomes between treatment and control groups, interpretation of the effects on clinical outcomes trajectories remains uncertain. A larger study is required to determine whether low-dose resveratrol may be beneficial.Research in context1.Systematic review: Human studies on low-dose resveratrol are scarce. This study aims to evaluate the safety, tolerability, and efficacy of an oral preparation of resveratrol, glucose, and malate (RGM) in slowing the progression of Alzheimer\'s disease.2.Interpretation: Results from this pilot study show less deterioration on the Alzheimer\'s Disease Assessment Scale--cognitive subscale, Mini--Mental State Examination, Alzheimer\'s Disease Cooperative Study--Activities of Daily Living Scale, and Neuropsychiatric Inventory in the treatment than the control group, although change scores were not statistically significance. No adverse effects were deemed to be study related.3.Future directions: Low-dose oral resveratrol is safe and well tolerated. Interpretation of the effects on clinical outcomes trajectories remains uncertain. A larger study is required to determine whether low-dose resveratrol may be beneficial.
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[^1]: Abbreviations: ADAS-cog, Alzheimer\'s Disease Assessment Scale--cognitive subscale; MMSE, Mini--Mental State Examination; ADCS-ADL, Alzheimer\'s Disease Cooperative Study--Activities of Daily Living Scale; NPI, Neuropsychiatric Inventory.

[^2]: Abbreviations: ADAS-cog, Alzheimer\'s Disease Assessment Scale--cognitive subscale; MMSE, Mini--Mental State Examination; ADCS-ADL, Alzheimer\'s Disease Cooperative Study--Activities of Daily Living Scale; NPI, Neuropsychiatric Inventory.

[^3]: Abbreviations: ADAS-cog, Alzheimer\'s Disease Assessment Scale--cognitive subscale; MMSE, Mini--Mental State Examination; ADCS-ADL, Alzheimer\'s Disease Cooperative Study--Activities of Daily Living Scale; NPI, Neuropsychiatric Inventory; GEE, generalized estimating equation.

[^4]: Includes depressed mood, wandering, low energy, drowsiness, depressed mood, agitation, and altered mental status.

[^5]: Facial flushing, dizziness, headache, tremors, and altered mental status.

[^6]: Diarrhea, constipation, abdominal discomfort, dry mouth, hematochezia, and worsening of inguinal hernia.

[^7]: Palpitations, presyncope vs. syncope, and congestive heart failure.

[^8]: Fall.

[^9]: Joint pain.

[^10]: Rash.

[^11]: Urinary discomfort.

[^12]: Anemia.

[^13]: Blurred vision and eye infection.
